AU2002333896B2 - Solid pharmaceutical formulation for a piperazine urea derivative - Google Patents

Solid pharmaceutical formulation for a piperazine urea derivative Download PDF

Info

Publication number
AU2002333896B2
AU2002333896B2 AU2002333896A AU2002333896A AU2002333896B2 AU 2002333896 B2 AU2002333896 B2 AU 2002333896B2 AU 2002333896 A AU2002333896 A AU 2002333896A AU 2002333896 A AU2002333896 A AU 2002333896A AU 2002333896 B2 AU2002333896 B2 AU 2002333896B2
Authority
AU
Australia
Prior art keywords
methyl
pharmaceutical agent
piperazine
agent formulation
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002333896A
Other languages
English (en)
Other versions
AU2002333896A2 (en
AU2002333896A1 (en
Inventor
Heiko Kranz
Ralph Lipp
Johannes Tack
Christoph Volkel
Herbert Wiesinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of AU2002333896A2 publication Critical patent/AU2002333896A2/en
Publication of AU2002333896A1 publication Critical patent/AU2002333896A1/en
Application granted granted Critical
Publication of AU2002333896B2 publication Critical patent/AU2002333896B2/en
Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT Request for Assignment Assignors: SCHERING AG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002333896A 2001-10-18 2002-10-07 Solid pharmaceutical formulation for a piperazine urea derivative Ceased AU2002333896B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10152351.3 2001-10-18
DE10152351A DE10152351B4 (de) 2001-10-18 2001-10-18 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
PCT/EP2002/011229 WO2003035037A1 (de) 2001-10-18 2002-10-07 Feste arzneimittelformulierung für ein piperazinharnstoffderivat

Publications (3)

Publication Number Publication Date
AU2002333896A2 AU2002333896A2 (en) 2003-05-06
AU2002333896A1 AU2002333896A1 (en) 2003-07-03
AU2002333896B2 true AU2002333896B2 (en) 2007-07-26

Family

ID=7703496

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002333896A Ceased AU2002333896B2 (en) 2001-10-18 2002-10-07 Solid pharmaceutical formulation for a piperazine urea derivative

Country Status (23)

Country Link
EP (1) EP1435917A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005506365A (cg-RX-API-DMAC7.html)
KR (1) KR20040047920A (cg-RX-API-DMAC7.html)
CN (1) CN1571660A (cg-RX-API-DMAC7.html)
AR (1) AR037111A1 (cg-RX-API-DMAC7.html)
AU (1) AU2002333896B2 (cg-RX-API-DMAC7.html)
BR (1) BR0213340A (cg-RX-API-DMAC7.html)
CA (1) CA2463951A1 (cg-RX-API-DMAC7.html)
CO (1) CO5580740A2 (cg-RX-API-DMAC7.html)
DE (1) DE10152351B4 (cg-RX-API-DMAC7.html)
EC (1) ECSP045108A (cg-RX-API-DMAC7.html)
HR (1) HRP20040435A2 (cg-RX-API-DMAC7.html)
IL (1) IL161166A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04003522A (cg-RX-API-DMAC7.html)
NO (1) NO20042022L (cg-RX-API-DMAC7.html)
NZ (1) NZ532287A (cg-RX-API-DMAC7.html)
PE (1) PE20030472A1 (cg-RX-API-DMAC7.html)
PL (1) PL367987A1 (cg-RX-API-DMAC7.html)
RS (1) RS32204A (cg-RX-API-DMAC7.html)
RU (1) RU2311172C2 (cg-RX-API-DMAC7.html)
UY (1) UY27500A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003035037A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200403781B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3909056B2 (ja) 2001-06-27 2007-04-25 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
EP1749519A1 (de) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
AU2007242077B2 (en) * 2006-04-26 2013-11-14 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
KR101654582B1 (ko) 2016-05-12 2016-09-06 그린로드(주) 원뿔형 부유 고분자 필터, 및 그의 제조장치 및 제조방법, 및 그를 포함하는 수처리 필터
RU2729223C1 (ru) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Дозированная форма для амплификации нуклеиновых кислот

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
ATE337307T1 (de) * 1998-02-05 2006-09-15 Pfizer Prod Inc Neue dihydroxyhexansäurederivate
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Steubel, A et al, J Controlled release, Vol 97 no 1 June 2000 pp101-110 *

Also Published As

Publication number Publication date
DE10152351B4 (de) 2005-09-22
CN1571660A (zh) 2005-01-26
MXPA04003522A (es) 2004-07-23
NO20042022L (no) 2004-05-14
AR037111A1 (es) 2004-10-20
PE20030472A1 (es) 2003-06-16
PL367987A1 (en) 2005-03-21
AU2002333896A2 (en) 2003-05-06
RU2004115328A (ru) 2005-06-10
EP1435917A1 (de) 2004-07-14
CA2463951A1 (en) 2003-05-01
HRP20040435A2 (en) 2005-06-30
RU2311172C2 (ru) 2007-11-27
BR0213340A (pt) 2004-10-05
JP2005506365A (ja) 2005-03-03
DE10152351A1 (de) 2003-05-08
WO2003035037A1 (de) 2003-05-01
KR20040047920A (ko) 2004-06-05
UY27500A1 (es) 2003-06-30
NZ532287A (en) 2007-04-27
RS32204A (sr) 2006-10-27
CO5580740A2 (es) 2005-11-30
IL161166A0 (en) 2004-08-31
ECSP045108A (es) 2004-06-28
ZA200403781B (en) 2004-11-29

Similar Documents

Publication Publication Date Title
JP6739470B2 (ja) デフェラシロクスの経口製剤
JP5366549B2 (ja) 即時放出特性及び/又は制御放出特性を有する薬学的剤形
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
JPH09511767A (ja) 新規な経口用の医薬使用形態
JP2008303223A (ja) 脈動用量薬剤経口送達システム
JP2017507928A (ja) アンドロゲン受容体アンタゴニストの固体医薬組成物
JP6759426B2 (ja) Cns化合物の安定化製剤
TW201534357A (zh) 延遲釋放型半胱胺珠粒調配物,以及其製備及使用方法
EP2090297A1 (en) Formulations of flibanserin
JP4705747B2 (ja) 薬剤組成物
JP4022269B2 (ja) 医薬組成物
EP1287821A1 (en) Multiparticulate formulations of atorvastatin calcium having a modulated rate of drug release
AU2002333896A2 (en) Solid pharmaceutical formulation for a piperazine urea derivative
AU2011235221A1 (en) Formulations of mazindol
WO2011064797A2 (en) Controlled release pharmaceutical compositions of galantamine
JP5124286B2 (ja) 徐放性製剤およびその製造方法
US20030087913A1 (en) Solid pharmaceutical agent formulation for a piperazine urea derivative
JP3929522B2 (ja) 難水溶性薬物の徐放性製剤
CZ287149B6 (en) Pharmaceutical preparation containing gemfibrozil
KR20230067636A (ko) 듀테트라베나진을 포함하는 다중미립자 제형
JPH06157313A (ja) ニカルジピン持続性製剤とその製造方法
CN113164396B (zh) 含有硫辛酸的固体药物制剂及其用途
AU2006335344A1 (en) Controlled release formulation of divalproic acid and its derivatives
US20030044459A1 (en) Biomodulated multiparticulate formulations
JP2006315971A (ja) イトラコナゾール経口投与製剤

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 JUL 2004

TC Change of applicant's name (sec. 104)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

Free format text: FORMER NAME: SCHERING AG

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ SOLID PHARMACEUTICAL FORMULATION FOR A PIPERAZINE UREA DERIVATIVE

MK14 Patent ceased section 143(a) (annual fees not paid) or expired